[go: up one dir, main page]

YU83903A - Farmaceutske kombinacije zasnovane na derivatima piridoindolona - Google Patents

Farmaceutske kombinacije zasnovane na derivatima piridoindolona

Info

Publication number
YU83903A
YU83903A YU83903A YUP83903A YU83903A YU 83903 A YU83903 A YU 83903A YU 83903 A YU83903 A YU 83903A YU P83903 A YUP83903 A YU P83903A YU 83903 A YU83903 A YU 83903A
Authority
YU
Yugoslavia
Prior art keywords
combinations based
pharmaceutical combinations
pyridoindolone derivatives
pyridoindolone
derivatives
Prior art date
Application number
YU83903A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of YU83903A publication Critical patent/YU83903A/sh
Publication of RS50791B publication Critical patent/RS50791B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak se odnosi na kombinacije jedinjenja formule: sa jednim ili više antikancerogenih agenasa.[The invention concerns the combination of compounds of formula (I) with several anticancer agents.
YUP-839/03A 2001-04-27 2002-04-26 Farmaceutske kombinacije zasnovane na derivatima piridoindolona RS50791B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (2)

Publication Number Publication Date
YU83903A true YU83903A (sh) 2006-08-17
RS50791B RS50791B (sr) 2010-08-31

Family

ID=8862882

Country Status (34)

Country Link
US (3) US6967203B2 (sh)
EP (2) EP1385512B1 (sh)
JP (2) JP2004528343A (sh)
KR (1) KR100847413B1 (sh)
CN (2) CN1505511A (sh)
AR (1) AR034313A1 (sh)
AT (2) ATE338548T1 (sh)
BG (2) BG108261A (sh)
BR (1) BR0209138A (sh)
CA (2) CA2443012C (sh)
CY (1) CY1105813T1 (sh)
CZ (2) CZ299465B6 (sh)
DE (2) DE60214533T2 (sh)
DK (2) DK1385512T3 (sh)
EA (1) EA005930B1 (sh)
EE (2) EE200300466A (sh)
ES (2) ES2271264T3 (sh)
FR (1) FR2823975B1 (sh)
HK (2) HK1059895A1 (sh)
HU (2) HUP0400745A2 (sh)
IL (4) IL158312A0 (sh)
IS (1) IS2441B (sh)
MX (1) MXPA03009639A (sh)
NO (2) NO20034785L (sh)
NZ (1) NZ528671A (sh)
PL (2) PL366910A1 (sh)
PT (2) PT1385513E (sh)
RS (2) RS50791B (sh)
RU (1) RU2292888C9 (sh)
SK (2) SK13252003A3 (sh)
TW (1) TWI252104B (sh)
UA (1) UA74876C2 (sh)
WO (2) WO2002087574A2 (sh)
ZA (1) ZA200307785B (sh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
JP2002510686A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
JP2004528343A (ja) 2004-09-16
KR100847413B1 (ko) 2008-07-18
IS2441B (is) 2008-11-15
IL158312A0 (en) 2004-05-12
WO2002087574A2 (fr) 2002-11-07
HUP0400744A2 (hu) 2004-06-28
CA2444334A1 (fr) 2002-11-07
PT1385513E (pt) 2007-01-31
RS50791B (sr) 2010-08-31
NO20034787D0 (no) 2003-10-24
ES2271264T3 (es) 2007-04-16
EP1385513B1 (fr) 2006-09-06
EE200300466A (et) 2003-12-15
US20040122027A1 (en) 2004-06-24
HK1059895A1 (en) 2004-07-23
WO2002087575A1 (fr) 2002-11-07
ATE314070T1 (de) 2006-01-15
DE60214533D1 (de) 2006-10-19
PT1385512E (pt) 2006-05-31
UA74876C2 (en) 2006-02-15
CN1505511A (zh) 2004-06-16
CY1105813T1 (el) 2011-02-02
NO20034787L (no) 2003-12-23
EP1385512B1 (fr) 2005-12-28
CZ20032910A3 (en) 2004-07-14
SK13242003A3 (sk) 2004-03-02
CZ295224B6 (cs) 2005-06-15
US7160895B2 (en) 2007-01-09
DE60208365T2 (de) 2006-09-07
EP1385513A1 (fr) 2004-02-04
HUP0400745A2 (hu) 2004-08-30
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
WO2002087574A3 (fr) 2003-02-13
RU2003130376A (ru) 2005-04-10
NZ528671A (en) 2004-06-25
CN1240382C (zh) 2006-02-08
BR0209138A (pt) 2004-06-08
ES2254683T3 (es) 2006-06-16
CN1505510A (zh) 2004-06-16
JP2004531538A (ja) 2004-10-14
TWI252104B (en) 2006-04-01
EE200300465A (et) 2003-12-15
RU2292888C2 (ru) 2007-02-10
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
EA200301062A1 (ru) 2004-04-29
PL366916A1 (en) 2005-02-07
BG108260A (bg) 2004-12-30
HK1060066A1 (en) 2004-07-30
CA2443012C (fr) 2009-07-28
NO20034785D0 (no) 2003-10-24
CZ299465B6 (cs) 2008-08-06
RS50790B (sr) 2010-08-31
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
SK13252003A3 (sk) 2004-03-02
DK1385512T3 (da) 2006-05-22
MXPA03009639A (es) 2004-06-30
CZ20032909A3 (en) 2004-06-16
DK1385513T3 (da) 2007-01-15
US20040122036A1 (en) 2004-06-24
EA005930B1 (ru) 2005-08-25
KR20040015138A (ko) 2004-02-18
US20050272760A1 (en) 2005-12-08
CA2443012A1 (en) 2002-11-07
IL158312A (en) 2009-09-01
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
AR034313A1 (es) 2004-02-18
US6967203B2 (en) 2005-11-22
IS6984A (is) 2003-10-09
FR2823975A1 (fr) 2002-10-31
US7524857B2 (en) 2009-04-28
PL366910A1 (en) 2005-02-07
YU83403A (sh) 2006-08-17
ZA200307785B (en) 2004-10-06
IL158266A (en) 2009-09-01
DE60214533T2 (de) 2007-06-21

Similar Documents

Publication Publication Date Title
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
GB0124627D0 (en) Novel compounds
HK1068626A1 (en) Chemical compounds
DE60112974D1 (en) Carbolinderivate
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
YU65802A (sh) Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
MX255195B (es) Composicion funguicida basada en derivados de arilamidina y compuestos fungicos conocidos.
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (es) Compuestos quimicos.
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
AU2003290592A1 (en) Antitumor benzoylsulfonamides
MXPA03009602A (es) Analogos de nociceptina.
TWI256304B (en) Pharmaceutical compositions based on azetidine derivatives
IL166483A0 (en) Pharmaceutical compositions containing ciclesonideand an antihistamine
MXPA04003755A (es) Endoprotesis vasculares.
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
GB9918429D0 (en) Organic compounds
DE60201074D1 (en) Pyrazolopyridinderivate
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents